Drugs / GQ1005
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06154343 | Nov 2022 → Dec 2024 | carcinoma | GeneQuantum Healthcare (Suzhou) Co., Ltd. | Unknown | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07673029 | Jan 2025 → Jan 2027 expected | HER2 positive breast carcinoma | GeneQuantum Healthcare (Suzhou) Co., Ltd. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2024-09-14 | GeneQuantum Healthcare (Suzhou) Co., Ltd. | Results WCLC 2024: The latest research results of the new generation HER2 ADC GQ1005 are unveiled genequantum.com ↗
On September 10, local time, GeneQuantum released the latest data of the first human study (FIH) of a novel HER2-ADC GQ1005 in HER2-expressing or HER2- mutated advanced solid tumors in the form of an oral report at the conference. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-08-19 | GeneQuantum Healthcare (Suzhou) Co., Ltd. | Breaking News! GeneQuantum and Henlius Entered into Strategic Cooperation to Jointly Advance the Commercialization of Innovative ADC Drug GQ1005 genequantum.com ↗ |
| 2024-09-14 | GeneQuantum Healthcare (Suzhou) Co., Ltd. | WCLC 2024: The latest research results of the new generation HER2 ADC GQ1005 are unveiled genequantum.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GQ1005 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06154343 ↗ |
| Modality | Other / unclassified | “an antibody drug conjugate” NCT06154343 ↗ |
| Route | Intravenous | “GQ1005 will be administered intravenously every 21 days.” NCT06154343 ↗ |